ABT-418 盐酸盐

C₉H₁₄N₂O · HCl

202.68

MFCD11045960

24724395

NA.77

ABT-418 is an α4β2 agonist of nicotinic receptors.

ABT-418 hydrochloride has been used as a nicotinic acetylcholine receptor (nAChR) agonist to test its effect on spatial memory improvement in attention deficit hyperactivity disorder (ADHD) rat model
ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. ABT-418 hydrochloride has been used to study new therapeutic approaches for the treatment of Alzheimer′s disease.

Neuronal nicotinic acetylcholine receptor agonist with cognition enhancing and anxiolytic activities.

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Subject to U.S. Patent No. 5409946 and sold under license from Abbott Laboratories.

100

≥98% (HPLC)

powder

desiccated

H₂O: soluble 15 mg/mL

Abbott

Cl.CN1CCC[C@H]1c2cc(C)no2

1S/C9H14N2O.ClH/c1-7-6-9(12-10-7)8-4-3-5-11(8)2;/h6,8H,3-5H2,1-2H3;1H/t8-;/m0./s1

VOXHERKWAIEJQF-QRPNPIFTSA-N

5, 25 mg in glass bottle

GHS06

Danger

H300 + H310 + H330

P262 - P280 - P301 + P310 + P330 - P302 + P352 + P310 - P304 + P340 + P310

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK 3